Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Haemonetics (HAE) Assets (2016 - 2025)

Haemonetics has reported Assets over the past 16 years, most recently at $2.5 billion for Q4 2025.

  • For Q4 2025, Assets fell 1.6% year-over-year to $2.5 billion; the TTM value through Dec 2025 reached $2.5 billion, down 1.6%, while the annual FY2025 figure was $2.5 billion, 11.63% up from the prior year.
  • Assets for Q4 2025 was $2.5 billion at Haemonetics, up from $2.4 billion in the prior quarter.
  • Over five years, Assets peaked at $2.5 billion in Q2 2024 and troughed at $1.8 billion in Q3 2021.
  • A 5-year average of $2.1 billion and a median of $2.0 billion in 2023 define the central range for Assets.
  • Biggest five-year swings in Assets: skyrocketed 43.63% in 2021 and later dropped 3.29% in 2025.
  • Year by year, Assets stood at $1.8 billion in 2021, then increased by 4.25% to $1.9 billion in 2022, then grew by 17.16% to $2.2 billion in 2023, then increased by 15.04% to $2.5 billion in 2024, then dropped by 1.6% to $2.5 billion in 2025.
  • Business Quant data shows Assets for HAE at $2.5 billion in Q4 2025, $2.4 billion in Q3 2025, and $2.5 billion in Q2 2025.